Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Thyrotropin alfa** is a recombinant human thyroid-stimulating hormone used as an adjunct in the management of **well-differentiated thyroid cancer** after thyroidectomy. Developed by **Genzyme** and marketed as **Thyrogen**, it is a biologic recombinant glycoprotein that **agonizes the thyroid-stimulating hormone receptor**, stimulating residual thyroid tissue or differentiated thyroid cancer cells to increase **thyroglobulin release** and **radioiodine uptake**. Clinically, it is used to facilitate serum thyroglobulin testing with or without radioiodine imaging during follow-up, and to prepare appropriate patients for radioiodine remnant ablation while allowing them to remain on thyroid hormone replacement, thereby avoiding hypothyroid withdrawal.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thyrotropin alfa.